Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?
AbstractPelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases. They had received a total of 175 treatments with Melphalan hypoxic perfusion and cytoreductive excision. Among the 41 patients, 22 (53.7%) patients exhibited a wild-type BRAF genotype, 11 of which were not eligible for immunotherapy. The first treatment resulted in a 97.5% response-rate in the full cohort and a 100% response-rate in the 22 wild-type BRAF patients. MST was 18 months in the full sample, 20 months for the 22 wild-type BRAF patients and 21 months for the 11 wild-type BRAF patients not eligible for immunotherapy. Melphalan hypoxic perfusion is a potentially effective treatment for patients with pelvic melanoma loco regional metastases that requires confirmation in a larger multicenter study. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Guadagni, S.; Fiorentini, G.; Clementi, M.; Palumbo, G.; Palumbo, P.; Chiominto, A.; Baldoni, S.; Masedu, F.; Valenti, M.; Tommaso, A.D.; Fabi, B.; Aliberti, C.; Sarti, D.; Guadagni, V.; Pellegrini, C. Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma? Int. J. Mol. Sci. 2017, 18, 2382.
Guadagni S, Fiorentini G, Clementi M, Palumbo G, Palumbo P, Chiominto A, Baldoni S, Masedu F, Valenti M, Tommaso AD, Fabi B, Aliberti C, Sarti D, Guadagni V, Pellegrini C. Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma? International Journal of Molecular Sciences. 2017; 18(11):2382.Chicago/Turabian Style
Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; Palumbo, Giancarlo; Palumbo, Paola; Chiominto, Alessandro; Baldoni, Stefano; Masedu, Francesco; Valenti, Marco; Tommaso, Ambra Di; Fabi, Bianca; Aliberti, Camillo; Sarti, Donatella; Guadagni, Veronica; Pellegrini, Cristina. 2017. "Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?" Int. J. Mol. Sci. 18, no. 11: 2382.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.